Glycogen Metabolism's Role in Alzheimer's Disease

Recent studies have highlighted a pressing connection between sugar metabolism and neurodegenerative diseases, particularly Alzheimer’s disease. The findings suggest that manipulating glycogen metabolism may hold promise in mitigating the effects of dementia, particularly Alzheimer’s. This may represent a significant advancement not only in our understanding of the disease but also in potential therapeutic interventions.

Understanding Glycogen's Role in the Brain

Glycogen, primarily known as a form of stored glucose, plays a critical role in energy production throughout the body. Although largely found in the liver and muscles, it also exists in brain cells, such as astrocytes and neurons. Abnormal aggregation of the microtubule-associated protein tau (MAPT), or simply tau protein, is a defining feature of several neurodegenerative diseases, most notably Alzheimer’s disease, where hyperphosphorylated neurofibrillary tangles (NFTs) can cause neuronal damage.

Research indicates that impaired glycogen metabolism in neuronal cells adversely impacts important cognitive functions such as learning and memory. Conversely, caloric restriction (CR) has been shown to extend lifespan and delay neurodegeneration in various experimental models. A recent study published in Nature Metabolism by scientists at the Buck Institute for Research on Aging aimed to explore the interplay between these two phenomena.

Caloric Restriction and Lifespan Extension

The researchers initiated their study using two transgenic Drosophila fly models: one that exhibited accelerated tau accumulation and another carrying a mutation in MAPT (R406W), which is associated with frontotemporal lobar degeneration with tau inclusions (FTLD-tau) in humans. The experiment subjected the flies to two distinct feeding regimens: ad libitum (freely fed) and dietary restriction (DR).

The results were striking:

• Increased Lifespan: DR significantly increased the lifespan of both healthy and diseased fly models. In disease models, the lifespan extension was dramatic, rescuing lifespan in flies with abnormal wild-type tau accumulation almost entirely.
• Reduction in Neuronal Death: Neuronal death in DR flies diminished substantially, indicating a protective effect.

Proteomic analyses illuminated shifts in metabolic pathways associated with fat and glycogen metabolism. Notably, even though levels of glycogen did not significantly change, the rate of glycogen turnover appeared to be a critical factor in this protection.

Glycogen Turnover and Antioxidants

Further investigations uncovered a fascinating dynamic where the enzyme glycogen phosphorylase (GlyP) was upregulated in mutant flies undergoing dietary restriction, leading to an impressive lifespan extension of around 70%, coupled with decreased neuronal death.

Interestingly, metabolomics and RNA sequencing analyses indicated that key pathways for energy production, including glycolysis and the citric acid cycle, were downregulated. Instead, glucose derived from glycogen was directed into the pentose phosphate pathway (PPP), which primarily generates antioxidants—essential molecules that mitigate oxidative stress.

This data suggests that a robust interaction between glycogen metabolism and oxidative stress plays a vital role in neuronal health, especially in tauopathies.

The Vicious Cycle of Tau and Glycogen Accumulation

In addition to studying Drosophila, the research team conducted in vitro experiments using human neurons derived from induced pluripotent stem cells (iPSCs) obtained from FTLD-tau patients. The findings demonstrated that tau proteins and glycogen co-localize and interact within cells, supporting the hypothesis that tau may promote glycogen accumulation, resulting in a detrimental feedback loop.

“Our findings suggest that glycogen is more than just a metabolic reservoir – it may act as a sticky trap for tau, creating a dangerous feedback loop where tau promotes glycogen buildup, and glycogen in turn fuels tau aggregation,” explained the corresponding author of the study.

Potential Therapeutic Implications

The implications of these findings are noteworthy. Targeting the interaction between tau and glycogen might reveal novel therapeutic avenues for treating Alzheimer’s disease. The identification of small molecules capable of augmenting GlyP production or modulating glycolytic pathways could enhance neuroprotection and improve overall cognitive function.

Conclusion

This emerging focus on the metabolic pathways involved in tau pathology represents a promising shift in Alzheimer's research. Continued exploration of glycogen metabolism and its interactions with key neurodegenerative processes might lead to innovative strategies that address both the symptoms and underlying mechanisms of dementia.

References

[1] Bar, S., Wilson, K. A., Hilsabeck, T. A., et al. (2025). Neuronal glycogen breakdown mitigates tauopathy via pentose-phosphate-pathway-mediated oxidative stress reduction. Nature Metabolism, 1-17.

[2] Goedert, M., Eisenberg, D. S., & Crowther, R. A. (2017). Propagation of tau aggregates and neurodegeneration. Annual Review of Neuroscience, 40(1), 189-210.

[3] Mann, D. M. A., Sumpter, P. Q., Davies, C. A., & Yates, P. O. (1987). Glycogen accumulations in the cerebral cortex in Alzheimer’s disease. Acta Neuropathologica, 73, 181-184.